We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

78 hedge funds and large institutions have $293M invested in Progenics Pharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more capital invested

Capital invested by funds: $219M → $293M (+$73.6M)

20% more call options, than puts

Call options by funds: $1.33M | Put options by funds: $1.11M

15% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 13

3% more funds holding

Funds holding: 76 → 78 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

19% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 26

Holders
78
Holders Change
+2
Holders Change %
+2.63%
% of All Funds
2.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
15
Increased
21
Reduced
26
Closed
13
Calls
$1.33M
Puts
$1.11M
Net Calls
+$222K
Net Calls Change
+$55K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$11.5M
2
TM
Tiger Management
New York
+$6.43M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$4.82M
4
RA
Royce & Associates
New York
+$3.39M
5
FM
Forward Management
California
+$2.89M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$1.57M
2
Millennium Management
Millennium Management
New York
-$570K
3
BFA
BlackRock Fund Advisors
California
-$388K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$381K
5
WAM
Wolverine Asset Management
Illinois
-$376K
Name Holding Trade Value Shares
Change 		Change in
Stake
TI
26
Turner Investments
Pennsylvania
$1.01M +$968K +194,230 New
AIG
27
American International Group
New York
$917K +$12.3K +2,465 +1%
Marshall Wace
28
Marshall Wace
United Kingdom
$875K +$840K +168,657 New
WAM
29
Wolverine Asset Management
Illinois
$845K -$376K -75,392 -32%
PPA
30
Parametric Portfolio Associates
Washington
$742K +$169K +34,004 +31%
California State Teachers Retirement System (CalSTRS)
31
California State Teachers Retirement System (CalSTRS)
California
$667K +$7.12K +1,429 +1%
BCM
32
Bridgeway Capital Management
Texas
$593K – – –
Charles Schwab
33
Charles Schwab
California
$551K – – –
TA
34
Teachers Advisors
New York
$528K – – –
OAM
35
Oxford Asset Management
United Kingdom
$511K +$485K +97,257 New
AllianceBernstein
36
AllianceBernstein
Tennessee
$473K – – –
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$414K – – –
JG
38
Jefferies Group
New York
$389K -$274K -55,000 -42%
CHAM
39
Clear Harbor Asset Management
Connecticut
$362K +$237K +47,600 +215%
HK
40
Horizon Kinetics
New York
$349K – – –
Bank of America
41
Bank of America
North Carolina
$344K -$251K -50,345 -43%
ProShare Advisors
42
ProShare Advisors
Maryland
$328K -$62.7K -12,588 -17%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$320K +$307K +61,613 New
T. Rowe Price Associates
44
T. Rowe Price Associates
Maryland
$292K +$75.2K +15,100 +37%
LP
45
LMR Partners
United Kingdom
$292K +$281K +56,338 New
NFA
46
Nationwide Fund Advisors
Ohio
$282K +$648 +130 +0.2%
MLICM
47
Metropolitan Life Insurance Company (MetLife)
New York
$278K -$85.7K -17,190 -24%
Susquehanna International Group
48
Susquehanna International Group
Pennsylvania
$277K -$263K -52,776 -50%
Goldman Sachs
49
Goldman Sachs
New York
$254K -$51.5K -10,334 -17%
State Board of Administration of Florida Retirement System
50
State Board of Administration of Florida Retirement System
Florida
$235K – – –
1
2
3 4

PGNX Hedge Fund Activity: Q3 2014 in Review

78 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2014, worth a combined $293M — up 34% from $219M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PGNX positions and 13 closed out — a net gain of 2 holders — while 21 added to existing stakes and 26 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $11.5M. The largest seller was Sabby Management, exiting entirely with an estimated $1.57M sold.

  • 78 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2014, up from 76 in Q2 2014.
  • Funds reported $293M of Progenics Pharmaceuticals Inc stock for Q3 2014, up 34% quarter-over-quarter.
  • 15 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2014 and 13 closed out, a net change of +2 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2014 was Broadfin Capital, an estimated $11.5M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2014 was Sabby Management, an estimated $1.57M sold.

Based on aggregated 13F filings for Q3 2014.